




Supplementary Figure S1




Supplementary Figure S2



Supplementary Figure S3



Supplementary Figure S4



Supplementary Table S1. Clinical characteristics of T-ALL patients

Clinical characteristics of T-ALL patient

Patient No	Gender	Age	Subtype	WBC (×10 ⁹ /L)	Blasts (%)	Cytogenetics	Molecular mutations	Induction therapy	Status after induction therapy
1	M	18	T-ALL	41.72	8.5	48,XY,+7,i(9)(q10),del(10)(q2 2q24),del(14)(q24q32),+add(1 9)(p13) [15]/46,xy[5]	NOTCH1; PTEN	VDCLP	CRi

Abbreviations: T-ALL, T-cell Acute Lymphoblastic Leukemia; WBC, White Blood Cell; VDCLP, Vindesine + Daunorubicin + Cyclophosphamide + L-Asparaginase + Prednisone; CRi, Complete Remission with Incomplete Hematologic Recovery